XNAS · Healthcare · Biotechnology
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.77 | -0.69 | +10.39% | $0 | ✅ Beat | +2.40% | -7.36% | — |
| 2026-04-02 | Q4 2025 | -0.69 | -0.84 | -21.74% | $0 | ❌ Miss | -7.47% | -5.22% | +3.08% |
| 2025-11-12 |
| Q3 2025 |
| -0.78 |
| -0.70 |
| +10.26% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.87 | -0.94 | -8.05% | $0 | ❌ Miss | +0.00% | +10.29% | +11.43% |
| 2025-04-07 | Q4 2024 | -0.73 | -0.68 | +6.85% | $0 | ✅ Beat | -10.45% | -4.47% | +29.45% |
| 2024-11-13 | Q3 2024 | -0.67 | -0.85 | -26.87% | $0 | ❌ Miss | +2.54% | +2.30% | -8.18% |
| 2024-08-14 | Q2 2024 | -0.60 | -0.59 | +1.67% | $0 | ✅ Beat | +13.55% | +5.27% | +23.79% |
| 2024-05-08 | Q1 2024 | -0.51 | -0.56 | -9.80% | $0 | ❌ Miss | -1.34% | +6.00% | -24.84% |
Showing last 8 quarters.